Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2023 | 2023-12-31 | $675,000 | reported | |
| FY 2022 | 2022-12-31 | $951,000 | reported |
Unicycive Therapeutics, Inc. · CIK 1766140 · Engraved from SEC EDGAR
FY2025 figures · derived
Unicycive Therapeutics, Inc. is the 282nd largest of the 553 covered companies the SEC files under this code, by market cap. SIC 2834
Latest filing Nov 16, 2026
The us-gaap concepts with the most facts on file for this company.
Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2024 | $1.10M | — | $1.10M | — | 119.71M sh | +244.4% | — |
| FY2023 | $900.00K | — | $900.00K | — | 34.76M sh | +128.2% | — |
No reported open-market purchases or sales in the last 12 months.
Third Quarter 2026 Financial Results and Provides Business Update